TVARDI THERAPEUTICS, INC. Earnings Per Share (Basic)
TVARDI THERAPEUTICS, INC. (TVRD) reported Earnings Per Share (Basic) of -$0.69 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.69, a 235.29% decline year-over-year.
- TVARDI THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.73.
- TVARDI THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.77.
- TVARDI THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.59.
- TVARDI THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$2.46.
- TVARDI THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was -$11.42.
- TVARDI THERAPEUTICS, INC. earnings per share, basic for fiscal 2023 was -$26.26.
- TVARDI THERAPEUTICS, INC. earnings per share, basic for fiscal 2022 was -$19.12.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.69 10-Q · filed 2026-08-14 | -$1.41 10-Q · filed 2026-08-14 | -$2.19 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$2.78 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2026-03-31 | -$0.73 10-Q · filed 2026-05-08 | -$1.50 derived: net income ÷ weighted average shares · filed 2026-05-08 | -$2.09 derived: net income ÷ weighted average shares · filed 2026-05-08 | -$1.70 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-12-31 | -$0.77 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$1.36 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$0.96 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$2.46 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$0.59 10-Q · filed 2025-11-13 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$1.62 10-Q · filed 2025-11-13 | -$4.15 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-06-30 | $0.51 10-Q · filed 2026-08-14 | -$1.00 10-Q · filed 2026-08-14 | -$4.06 derived: net income ÷ weighted average shares · filed 2026-08-14 | -$5.92 derived: net income ÷ weighted average shares · filed 2026-08-14 | ||||
| 2025-03-31 | -$3.72 10-Q · filed 2026-05-08 | -$3.22 10-Q · filed 2025-05-13 | -$8.65 derived: net income ÷ weighted average shares · filed 2026-05-08 | -$10.80 derived: net income ÷ weighted average shares · filed 2026-05-08 | -$13.50 derived: net income ÷ weighted average shares · filed 2026-05-08 | |||
| 2024-12-31 | -$4.94 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$7.08 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$9.79 derived: net income ÷ weighted average shares · filed 2026-03-31 | -$11.42 10-K · filed 2026-03-31 | -$15.53 10-K · filed 2025-03-11 | |||
| 2024-09-30 | -$2.14 10-Q · filed 2025-11-13 | -$0.23 10-Q · filed 2024-11-14 | -$4.85 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$6.48 10-Q · filed 2025-11-13 | -$1.15 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | -$2.71 10-Q · filed 2025-08-14 | -$0.37 10-Q · filed 2024-08-14 | -$4.34 10-Q · filed 2025-08-14 | -$0.93 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | -$20.24 10-Q · filed 2025-05-13 | -$0.56 10-Q · filed 2024-05-13 | ||||||
| 2023-12-31 | -$26.26 10-K · filed 2025-03-11 | -$2.19 10-K · filed 2024-03-06 | ||||||
| 2023-09-30 | -$0.52 10-Q · filed 2024-11-14 | -$1.59 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | -$0.58 10-Q · filed 2024-08-14 | -$1.08 10-Q · filed 2024-08-14 | ||||||
| 2023-03-31 | -$0.49 10-Q · filed 2024-05-13 | |||||||
| 2022-12-31 | -$19.12 10-K · filed 2025-03-11 | -$1.59 10-K · filed 2023-03-06 | ||||||
| 2022-09-30 | -$0.43 10-Q · filed 2023-11-13 | -$1.03 10-Q · filed 2023-11-13 | ||||||
| 2022-06-30 | -$0.08 10-Q · filed 2023-08-07 | -$0.60 10-Q · filed 2023-08-07 | ||||||
| 2022-03-31 | -$0.52 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | -$1.74 10-K · filed 2024-03-06 | |||||||
| 2021-09-30 | -$0.02 10-Q · filed 2022-11-07 | -$1.10 10-Q · filed 2022-11-07 | ||||||
| 2021-06-30 | -$0.61 10-Q · filed 2022-08-08 | -$1.08 10-Q · filed 2022-08-08 | ||||||
| 2021-03-31 | -$0.47 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $1.60 10-K · filed 2021-02-25 | $0.18 10-K · filed 2023-03-06 | ||||||
| 2020-09-30 | -$0.35 10-K · filed 2021-02-25 | |||||||
| 2020-06-30 | -$0.54 10-K · filed 2021-02-25 | |||||||
| 2020-03-31 | -$0.62 10-K · filed 2021-02-25 | |||||||
| 2019-12-31 | -$2.49 10-K · filed 2022-03-01 | |||||||
| 2018-12-31 | -$2.06 10-K · filed 2021-02-25 | |||||||
| 2014-06-30 | -$0.16 10-Q · filed 2014-08-07 | -$0.37 10-Q · filed 2014-08-07 | ||||||
| 2013-12-31 | -$0.49 10-K · filed 2015-03-27 | -$1.55 derived: net income ÷ weighted average shares · filed 2016-03-11 | -$1.21 derived: net income ÷ weighted average shares · filed 2016-03-11 | -$1.68 derived: net income ÷ weighted average shares · filed 2016-03-11 | ||||
| 2013-09-30 | -$1.07 10-K · filed 2015-03-27 | -$0.72 derived: net income ÷ weighted average shares · filed 2015-03-27 | -$1.19 derived: net income ÷ weighted average shares · filed 2015-03-27 | |||||
| 2013-06-30 | $0.34 10-K · filed 2015-03-27 | $0.24 10-Q · filed 2014-08-07 | ||||||
| 2013-03-31 | -$0.48 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |